secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vistagen Therapeutics, Inc. (VTGN)
CIK:        0001411685
Form:       8-K
Filed at:   2023-09-08T23:59:59+00:00
Accession:  0001437749-23-025509
Event type: m_and_a
Sentiment:  positive
Materiality: 0.60
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vistagen enters exclusive negotiation with Fuji Pharma for PH80 in Japan; receives $1.5M upfront
--------------------------------------------------------------------------------

- Fuji Pharma pays $1.5M non-refundable for up to ~18-month exclusive negotiation for PH80 license in Japan.
- PH80 is a neuroactive nasal spray for acute treatment of moderate to severe menopausal hot flashes.
- Exploratory Phase 2A showed statistically significant reduction in hot flash frequency and severity vs placebo.
- If a definitive license agreement is signed, the $1.5M will be creditable against the signing fee.
- Neither party is obligated to reach a definitive agreement; negotiations may terminate after exclusive period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923025509/0001437749-23-025509-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1411685/000143774923025509/vtgn20230908_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-23-025509

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer